Participated · Series D · Sep 2024

eGenesis is a biotechnology company developing human-compatible engineered organs to address the global organ shortage. Its lead product candidate, the donor kidney EGEN-2784, carries three classes of genome edits: knockout of glycan-antigen synthesis genes, insertion of seven human transgenes to modulate rejection pathways, and inactivation of endogenous porcine retroviruses. The company’s EGEN genome engineering and production platform aims to comprehensively address cross-species molecular incompatibilities and viral risk. Proceeds from the $191 million Series D will be used to advance EGEN-2784 to a first-in-human kidney transplant study, advance pipeline programs (including acute liver failure and heart transplant), and scale production. In March 2024 eGenesis announced the world’s first successful porcine kidney transplant in a living patient under an FDA Expanded Access authorization, performed at Massachusetts General Hospital. The company says it is the only firm developing organs that carry all three classes of edits to address organ safety and efficacy. eGenesis develops human-compatible organs, tissues, and cells using gene-editing and genome-engineering to address barriers to xenotransplantation. The company harnesses gene editing technologies to make organs safe and effective for patients in need. Its development pipeline includes lead programs for kidney and islet cell transplants and earlier-stage programs targeting other solid organs. eGenesis intends to use its Series C proceeds to bring lead kidney and islet programs into human proof-of-concept studies, continue development of its proprietary gene-editing platform, and scale GMP production. The company is led by Paul Sekhri, President and Chief Executive Officer. Financially, eGenesis completed a $125m Series C financing in February 2021. eGenesis develops human-compatible organs using gene editing technologies such as CRISPR to overcome virology and immunology hurdles that have impeded xenotransplantation. The company is advancing an initial kidney product toward the clinic while pursuing programs in islet cell, liver, heart, and lung. It intends to use new funding to accelerate its kidney xenotransplant program into the clinic and to support advancement of other xenotransplant programs. eGenesis positions xenotransplantation as a potential solution for a broader organ recipient population and to expand applicability into areas such as cell therapy. The company is led by president and CEO Paul Sekhri and is based in Cambridge, Massachusetts. eGenesis completed a $100M Series B financing to support these efforts. eGenesis uses a CRISPR-based genome editing platform to engineer pig cells and organs intended for safe and effective human transplantation. The company’s core approach includes genomic engineering of pig cells, organ maturation, and eventual organ transplantation. eGenesis positions xenotransplantation as a solution to the severe shortage of transplantable human organs and aims to make it a routine lifesaving medical procedure. Its scientific team includes co-founder and CSO Luhan Yang and Harvard geneticist George Church, plus multiple scientists from Harvard with expertise in genome editing, synthetic biology, and transgenic animals. The company is in early stages of development and is advancing its platform toward delivering transplantable cells, tissues and organs. eGenesis announced a recent financing to support these development efforts.

Participated · Series C · May 2024

Memo Therapeutics is a late-stage biotech company based in Schlieren, Zurich, developing therapeutic antibodies for viral infections and cancer. Its lead program, AntiBKV, is a neutralizing antibody aimed at treating BK virus infection in kidney transplant recipients. The company holds FDA fast track status for AntiBKV and intends to use new funds to accelerate clinical development. Memo plans to expand its Phase II trial with a dose-evaluation extension supported by the financing. Its pipeline includes additional antibody candidates targeting infectious diseases such as cytomegalovirus (CMV) and immuno-oncology programs, including a partnership with Ono Pharmaceutical. The company is led by CEO Erik van den Berg. Memo Therapeutics AG (MTx) is a late-stage biotech based in Schlieren/Zurich, Switzerland, focused on developing best-in-class therapeutic antibodies for viral infections and cancer. Its lead program, AntiBKV, is a highly effective neutralizing antibody designed to treat BK polyomavirus infection in kidney transplant recipients, a condition that can lead to graft dysfunction and organ rejection. MTx plans to complete a multi-center U.S. Phase II study of AntiBKV and is preparing to scale up CMC manufacturing for a Phase III study and potential market entry. The company expects Phase II clinical data in 2024 and is preparing for a potential launch in 2025. Proceeds from its recent financing will also be used to advance additional pipeline candidates targeting infectious diseases such as CMV and immuno-oncology targets, and to support a partnership with Ono Pharmaceutical. Memo Therapeutics develops antibody discovery and immune repertoire analysis technologies that capture whole B-cell repertoires from any donor species and screen them in single-cell format to identify functional monoclonal antibodies. Its platform uses microfluidic single-cell molecular cloning and screening to assess millions of candidate antibodies and generate recombinant clonal cell lines expressing desired mAbs. The company’s pipeline focuses on infectious diseases and immuno‑oncology, with lead programs MTX-005 (a neutralizing antibody targeting BK virus) and COVAB 36 (an inhaled monoclonal antibody for SARS-CoV-2). Memo plans to use the new funding to advance MTX-005 into Phase 2 clinical development, expand its antibody pipeline, and secure new partnering agreements. The company also lists programs in cytomegalovirus (CMV) and Nipah virus, and says the recent funding together with a Swiss Federal COVID-19 grant will enable advancement of MTX-005 and COVAB 36 into clinical development this year. Memo Therapeutics is a private company based in Bio‑Technopark Zurich, Switzerland. Memo Therapeutics uses a droplet microfluidics-based single-cell platform (Dropzylla®) to capture and preserve entire B-cell repertoires and screen millions of candidate antibodies in functional assays. The platform generates recombinant clonal cell lines expressing monoclonal antibodies and is applied across species and indications for proprietary and partnered projects. The company’s pipeline includes programs in infectious diseases and immuno-oncology; its lead COVID-19 program is COVAB 36, a potent, fully-human monoclonal antibody that can be administered via inhalation. Memo received CHF 10.5 million from the Swiss Federal Funding Programme for COVID-19 Medicines to clinically develop COVAB 36, with the programme implemented by the Swiss Federal Office of Public Health and supported by Innosuisse. Memo completed preclinical development and plans to start phase 1 clinical studies with COVAB 36 in Q1 2022, and the project includes rapid development of a combination antibody partner for emerging variants via an ultra-fast update process. The company is a private firm located in Bio‑Technopark Zurich and was ranked in the TOP 100 Swiss Startups list from 2015 to 2017. Memo Therapeutics AG develops antibody discovery and immune repertoire analysis technologies built on microfluidic single-cell molecular cloning and screening. Its platform captures and preserves entire B-cell repertoires and screens them in single-cell format, assessing millions of candidate antibodies directly in functional assays to produce recombinant clonal cell lines expressing monoclonal antibodies with desired functions. The company’s pipeline includes infectious disease and immuno-oncology programs, with lead assets MTX-COVAB for COVID-19 and MTX-005 for BK virus in renal transplant patients. Memo says MTX-COVAB is a fully human, highly potent antibody that neutralizes all major known mutants and that it has agreed a fast-track development plan with regulators, planning to begin clinical studies in 2021. The CHF 14 million Series B financing will primarily fund advancement of MTX-COVAB through Phase II and GMP production, Phase II development of MTX-005, and expansion of additional anti-infectious candidates and partnering activities. The company is located in Bio-Technopark Zurich, Schlieren, Switzerland.

Led · Series B · Jul 2022

Retia Medical develops advanced hemodynamic monitoring solutions centered on its Argos Cardiac Output Monitor and proprietary Multi-Beat Analysis (MBATM) algorithm. The Argos Monitor provides accurate, real-time cardiac output and hemodynamic data by analyzing multiple heartbeats and leverages a patient’s existing arterial line without requiring additional disposables. The system is designed for high-risk surgical and critically ill patients, enabling individualized, data-driven care to improve outcomes and lower costs. The next-generation Argos Monitor can be set up in less than one minute and detects important changes in a patient’s status to enable immediate clinical intervention. The company combines expertise in physiology, signal processing, data science, and computational algorithms to engineer its products. Retia will use the new funding to expand its commercial team and accelerate development of next-generation algorithms for guiding care for high-risk patients. Retia Medical is a medical device company based in East Lansing, Mich., developing a less-invasive system to monitor cardiac output and other key measures of the cardiovascular system. Its core platform technology was developed at Michigan State University. The company says the monitor can provide accurate measurements when patients go into shock. Retia was co-founded by Rama Mukkamala and CEO Marc Zemel. The company raised $7M in a Series A financing led by the Pritzker/Vlock family office. It intends to use the proceeds to complete product development, submit regulatory filings and launch its minimally invasive cardiac output monitor.

Participated · Series B · Jan 2019

Modulated Imaging develops medical-photonics and informatics solutions powered by its Spatial Frequency Domain Imaging (SFDI) platform to assess tissue health. Its core product, the FDA-cleared Clarifi Imaging System, provides quantitative assessment of circulatory compromise to help identify patients at risk for diabetic foot ulcers and other vascular complications. The SFDI technology measures microvascular tissue oxygenation and hemoglobin concentration and distribution to detect compromised perfusion early. The company positions Clarifi to enable earlier clinical intervention with the potential to save limbs and lives and reduce treatment costs. Recent financing is being used to advance commercialization of Clarifi and broaden clinical adoption. Modulated Imaging develops light-based, non-invasive imaging systems (Ox-Imager CS) that provide both surface and subsurface views plus a digital color photograph to assess tissue health and identify lower-limb vascular issues. The company received FDA clearance earlier this year for the Ox-Imager CS. Proceeds from its recent financing will support key clinical studies — expanding trials beyond California and Arizona — and accelerate development of a miniaturized next-generation Ox-Imager device. Modulated Imaging closed a $2.86 million Series A and also received a $1.2 million Commercialization Readiness grant from NIAMS (NIH). This financing is the company's second round since July of last year. The company was founded in 2008 and is based in Irvine, Calif. Modulated Imaging is an Irvine, CA–based developer of imaging systems for scientific and medical applications. The company develops patented Spatial Frequency Domain Imaging (SFDI) tissue-imaging devices intended to help medical, research and aesthetics professionals prevent, diagnose and treat underlying skin conditions. Its first medical device, the Ox-Imager CS, is pending FDA clearance and is targeted to rapid, wide-area perfusion studies across applications from vascular labs to chronic wound management. Modulated Imaging also sells the Reflect RS scientific instrument. The company has been self-funded through sales of the Reflect RS and approximately $8M in research grants from the National Institutes of Health and the Department of Defense. It intends to use the newly raised funds to continue development of its medical technology.

Participated · Series B · Dec 2018

Tridiuum offers a cloud-based behavioral health outcomes management platform, Tridiuum1, that uses predictive analytics and a proprietary Behavioral Health Index to identify, treat, and manage behavioral health across the continuum of care. The platform delivers actionable insights at the point of care and can integrate with most electronic health records and health-IT software. Today more than 600 clinical facilities and over 2,500 behavioral health providers use the platform to assess more than 4,000 patients a day. The company reports customer revenue is up 307% since 2015 and has recently expanded office space, tripling its footprint from Wayne, Pa. to a larger Philadelphia Center City location at 1650 Arch Street. Management plans to use the new funding to expand sales, marketing, and strategic product development, and has hinted at major new features in the works.